{"organizations": [], "uuid": "ddb6901074db8ebd4ca753e259488686ae60fd78", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530761?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Euroscreen closes €16mm Series B round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Euroscreen closes €16mm Series B round", "spam_score": 0.0, "site_type": "news", "published": "2015-10-20T02:41:00.000+03:00", "replies_count": 0, "uuid": "ddb6901074db8ebd4ca753e259488686ae60fd78"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530761?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Euroscreen closes €16mm Series B round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Euroscreen closes €16mm Series B round Deal Date: Oct-01-2015 / Deal # 201530761 Executive Summary \nEuroscreen SA (treatments for women's health conditions and neurodegenerative diseases) raised €16mm ($18mm) through its Series B round. SFPI-FPIM and Fund+ NV co-led and were joined by returning investors Vesalius Biocapital II Partners, SRIW SA (Société Régionale d'Investissement de Wallonie), BNP Paribas Fortis Private Equity, and new backer Capricorn Health-Tech Fund NV. Funds will support lead candidate ESN364 (menopausal hot flashes, polycystic ovary syndrome (PCOS), and uterine fibroids), including IND filing in the US, long-term toxicology studies, and Phase II trials.", "external_links": [], "published": "2015-10-20T02:41:00.000+03:00", "crawled": "2015-10-20T19:21:23.715+03:00", "highlightTitle": ""}